Banner

PDT + triamcinolone shows promise as treatment for non-subfoveal CNV

Article

Short-term results from a small study suggest combined verteporfin (Visudyne,Novartis) photodynamic therapy (PDT) with intravitreal triamcinolone meritsadditional investigation for the treatment of non-subfoveal CNV, said RichardF. Spaide, MD.

Related Videos
Related Content

Novartis finalizes divestment of ‘front of eye’ ophthalmology assets

September 30th 2023

EyePod: Week in Review - September 24, 2023

September 30th 2023

Outlook Therapeutics requests Type A meeting with FDA

September 29th 2023

EyePod: Transforming the MIGS pipeline into clinical reality

September 26th 2023

BLOG: MicroPulse TLT for patients who struggle with drops

September 29th 2023

Digital healthcare startup eyecbetter kicks off Regulation C crowdfunding campaign on StartEngine

September 28th 2023

Novartis finalizes divestment of ‘front of eye’ ophthalmology assets

September 30th 2023

EyePod: Week in Review - September 24, 2023

September 30th 2023

Outlook Therapeutics requests Type A meeting with FDA

September 29th 2023

EyePod: Transforming the MIGS pipeline into clinical reality

September 26th 2023

BLOG: MicroPulse TLT for patients who struggle with drops

September 29th 2023

Digital healthcare startup eyecbetter kicks off Regulation C crowdfunding campaign on StartEngine

September 28th 2023

Novartis finalizes divestment of ‘front of eye’ ophthalmology assets

September 30th 2023

EyePod: Week in Review - September 24, 2023

September 30th 2023

Outlook Therapeutics requests Type A meeting with FDA

September 29th 2023

EyePod: Transforming the MIGS pipeline into clinical reality

September 26th 2023

BLOG: MicroPulse TLT for patients who struggle with drops

September 29th 2023

Digital healthcare startup eyecbetter kicks off Regulation C crowdfunding campaign on StartEngine

September 28th 2023
© 2023 MJH Life Sciences

All rights reserved.